Wedbush Reiterates Outperform on Surface Oncology, Maintains $3 Price Target
Wedbush analyst Robert Driscoll reiterates Surface Oncology (NASDAQ:SURF) with a Outperform and maintains $3 price target.
Surface Oncology Announced Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that findings from a study interrogating the role of the IL-27 pathway in the development of hepatocellular carcinoma (HCC) have been published in the onli
Surface Oncology Q1 EPS $0.13 Up From $(0.37) YoY
Surface Oncology (NASDAQ:SURF) reported quarterly earnings of $0.13 per share. This is a 135.14 percent increase over losses of $(0.37) per share from the same period last year.
